Watchlist

Watchlist
Astrazeneca PLC (AZN)
Biotech Analysis Central Pharma News: Roche's MS Win, Aradigm FDA Panel Woes, AstraZeneca's Expanded Indication
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Roche Wins European Approval For Multiple Sclerosis Drug News: Recently, Roche ( OTCQX:RHHBY ) won European approval for its Multiple Sclerosis (MS) …
3 Things In Biotech You Should Learn Today: January 13, 2018
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AstraZeneca scores an historic approval for PARP inhibitors Company: AstraZeneca ( AZN ) …
Week In Review: Hua Medicine To Raise $200 Million Through Fundings And IPO For Oral Diabetes Drug
Deals and Financings Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US. The funds will underwrite Phase …
Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day
Today we will discuss the Ad Com's vote against Lipocine's ( LPCN ) TLANDO. The news sparked a huge sell-off in LPCN on Wednesday. Few days before the Ad Com, we had written a note on LPCN, highlighting that it is a binary event. TLANDO had been rejected by the FDA in 2016, which pushed LPCN…
LYNPARZA® (olaparib) Approved by US FDA in Germline BRCA-Mutated Metastatic Breast Cancer
LYNPARZA is the first and only PARP inhibitor approved for use beyond ovarian cancer LYNPARZA reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy AstraZeneca and Merck (Merck: known as MSD outside the US and Canada) today announce…
PARP competitors under pressure as AstraZeneca nabs U.S. OK for Lynparza in BRCA-positive breast cancer
Clovis Oncology ( CLVS -1.4% ) and TESARO ( TSRO -2% ) have been under near-term pressure, down 13% and 16% , respectively, since the end of 2017, as buying picks up in AstraZeneca ( AZN +0.8% ), up 12% since early December, as the competition heats up in …
FDA OKs AstraZeneca's Lynparza BRCA-mutated breast cancer; shares up 1%
The FDA approves AstraZeneca's ( AZN +0.8% ) PARP inhibitor LYNPARZA (olaparib) for the treatment of HER2-negative breast cancer patients whose tumors harbor the BRCA genetic mutation. More news on: AstraZeneca Group plc, Myriad Genetics, Inc., Healthcare stocks news, Stocks on the m…
Your Daily Pharma Scoop: AbbVie Highlights Pipeline, Novavax Surges, Lipocine Flops At Ad Com
Analysis of top Seeking Alpha coverage: AbbVie Today we will discuss one of the most promising major biopharma companies, AbbVie ( ABBV ). At the ongoing JP Morgan Healthcare Conference, ABBV CEO Rick Gonzalez gave an overview of the pipeline and financials. The companys pipeline i…
AstraZeneca's Fasenra OK'd in Europe
As expected, the European Commission approves AstraZeneca's ( AZN -0.8% ) Fasenra (benralizumab) as add-on maintenance treatment in adult patients with severe inadequately controlled eosinophilic asthma despite high-dose inhaled corticosteroids plus long-acting beta-agonists. More news…
Start of JPM18 fails to buoy healthcare stocks
The start of JPMorgan's healthcare conference has started with a whimper with no significant news to boost biopharma or biotech stocks. Most issues are under pressure in early trading. More news on: Gilead Sciences, Inc., Celgene Corporation, Vertex Pharmaceuticals Incorporated, Healthcare…
Biotech Analysis Central Pharma News: Allergan's Restasis Trouble, Mylan's Advance On Teva, Pfizer's Alzheimer's Exit
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Allergan To Cut 1,000 Jobs As A Generic Restasis Sets To Take Stage News: Recently, Allergan ( AGN ) announced that it would cut up to 1,000 jobs t…
Astrazeneca PLC (AZN)